Greenbrook TMS Inc. (GBNH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Greenbrook TMS Inc. (GBNH) trades at $0.12 with AI Score 45/100 (Grade C). Greenbrook TMS Inc. Market cap: $5.52M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for GBNH: GBNH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GBNH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GBNH: the 1 perspectives are evenly split.
How is this calculated? →Greenbrook TMS Inc. (GBNH) Healthcare & Pipeline Overview
Greenbrook TMS Inc. provides transcranial magnetic stimulation (TMS) therapy for mental health disorders, operating a network of outpatient centers across the United States. With a focus on non-invasive treatments for depression, Greenbrook distinguishes itself through specialized psychiatric services within the evolving mental healthcare landscape.
What Is the Investment Thesis for GBNH?
Greenbrook TMS Inc. presents a focused investment opportunity within the mental healthcare sector, specifically in the provision of TMS therapy. The company's network of centers across the United States provides a platform for growth in a market with increasing demand for non-invasive mental health treatments. Key value drivers include expanding the number of operational centers and increasing patient throughput at existing locations. The company's negative P/E ratio of -0.03 and a negative profit margin of -125.5% highlight the challenges in achieving profitability. Upcoming catalysts include potential expansion into new geographic markets and the introduction of additional mental health services. Potential risks include competition from alternative treatment options and the need for continued investment in infrastructure and technology.
Based on FMP financials and quantitative analysis
GBNH Key Highlights
- Market capitalization of $5.52M, reflecting its small-cap status.
- Negative P/E ratio of -0.03, indicating current losses.
- Gross margin of 8.8%, highlighting challenges in profitability.
- Operates 94 wholly owned and 55 TMS centers as of December 31, 2021.
- Beta of 1.74, suggesting higher volatility compared to the market.
Who Are GBNH's Competitors?
GBNH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ENTO ENTO | $2.85 | -5.00% | $13.58M | 49 |
| LMDX LumiraDx Limited | $0.02 | +0.00% | $5.10M | 46 |
| MODV ModivCare Inc. | $0.43 | +0.00% | $6.20M | 47 |
| NSTG NanoString Technologies, Inc. | $0.11 | -37.43% | $5.07M | 51 |
| NUVO Holdco Nuvo Group D.G Ltd. Ordinary Shares | $0.17 | +100.00% | $5.65M | 49 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GBNH's Key Strengths?
- Specialized in TMS therapy.
- Established network of centers.
- FDA-cleared treatment.
- Focus on non-invasive treatments.
What Are GBNH's Weaknesses?
- Negative profit margin.
- High beta indicating volatility.
- Limited geographic presence.
- Reliance on insurance reimbursement.
What Could Drive GBNH Stock Higher?
- Potential expansion into new geographic markets.
- Introduction of additional mental health services.
- Increasing patient awareness of TMS therapy.
- Strategic partnerships with healthcare providers.
What Are the Key Risks for GBNH?
- Financial-distress signal — its Altman Z-Score of -0.72 sits in the distress zone (elevated bankruptcy risk).
- Competition from alternative treatment options.
- Changes in reimbursement policies.
- Economic downturn affecting patient affordability.
- Regulatory compliance challenges.
- Negative profit margin and financial instability.
What Are the Growth Opportunities for GBNH?
- Expansion into Underserved Markets: Greenbrook has the opportunity to expand its network of TMS centers into underserved geographic markets within the United States. Many rural and suburban areas lack access to specialized mental health services, creating a potential market for Greenbrook's TMS therapy. The timeline for this expansion depends on securing funding and regulatory approvals, but could contribute significantly to revenue growth within the next 3-5 years. This expansion would allow Greenbrook to capture a larger share of the mental health treatment market, estimated to reach $533 billion by 2030.
- Increased Patient Throughput: Greenbrook can focus on increasing patient throughput at its existing TMS centers. By optimizing scheduling, improving patient education, and streamlining the treatment process, Greenbrook can serve more patients with its existing infrastructure. This strategy can lead to higher revenue per center and improved profitability. The timeline for implementing these improvements is relatively short, with potential benefits realized within the next 1-2 years. This would improve the utilization of existing assets and drive revenue growth without significant capital expenditure.
- Strategic Partnerships with Healthcare Providers: Greenbrook can form strategic partnerships with hospitals, clinics, and other healthcare providers to integrate TMS therapy into their existing service offerings. These partnerships can provide Greenbrook with access to a broader patient base and referral network. The timeline for establishing these partnerships varies depending on the complexity of the agreements, but could generate significant revenue within the next 2-3 years. This collaborative approach would enhance Greenbrook's market reach and brand recognition.
- Development of New TMS Applications: Greenbrook can invest in research and development to explore new applications of TMS therapy for other mental health disorders beyond major depressive disorder. This could include treating anxiety, PTSD, and other conditions. Successful development of new TMS applications would expand Greenbrook's addressable market and create new revenue streams. The timeline for this research and development is longer, with potential breakthroughs and new product offerings emerging within the next 3-5 years. This would position Greenbrook as a leader in innovative mental health treatments.
- Telehealth Integration for Psychiatric Services: Greenbrook can integrate telehealth services to provide remote psychiatric consultations and follow-up care to patients. This would improve access to care, particularly for patients in remote areas or those with mobility issues. Telehealth integration can also reduce overhead costs and improve efficiency. The timeline for implementing telehealth services is relatively short, with potential benefits realized within the next 1-2 years. The global telehealth market is projected to reach $55.6 billion by 2027, presenting a significant opportunity for Greenbrook to expand its service offerings.
What Opportunities Does GBNH Have?
- Expansion into underserved markets.
- Increased patient throughput.
- Strategic partnerships.
- Development of new TMS applications.
What Threats Does GBNH Face?
- Competition from alternative treatments.
- Changes in reimbursement policies.
- Economic downturn affecting patient affordability.
- Regulatory challenges.
What Are GBNH's Competitive Advantages?
- Specialized expertise in TMS therapy.
- Established network of TMS centers across the United States.
- FDA-cleared treatment for major depressive disorder.
- Brand recognition in the mental health services market.
What Does GBNH Do?
Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS Inc. has established itself as a provider of outpatient mental health services in the United States. The company's core offering revolves around transcranial magnetic stimulation (TMS) therapy, an FDA-cleared, non-invasive treatment for major depressive disorder and other mental health disorders. Greenbrook operates a network of centers that provide TMS therapy alongside related psychiatric services. As of December 31, 2021, Greenbrook operated 94 wholly owned and 55 TMS centers across multiple states, including Virginia, Maryland, Delaware, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, Michigan, Alaska, Oregon, California, Iowa, and Massachusetts. These centers offer patients access to innovative mental health treatments, addressing a significant need in the healthcare sector. Greenbrook's business model centers on providing specialized care through its network of TMS centers, focusing on patient outcomes and expanding access to mental health treatments.
What Products and Services Does GBNH Offer?
- Operates a network of outpatient mental health service centers.
- Specializes in transcranial magnetic stimulation (TMS) therapy.
- Provides non-invasive treatment for major depressive disorder.
- Offers therapy for other mental health disorders.
- Provides related psychiatric services.
- Operates centers across multiple states in the United States.
How Does GBNH Make Money?
- Generates revenue by providing TMS therapy to patients.
- Revenue is also generated through related psychiatric services.
- Operates on a fee-for-service basis, billing insurance companies and patients directly.
What Industry Does GBNH Operate In?
Greenbrook TMS Inc. operates within the medical care facilities industry, a segment of the broader healthcare sector. The industry is characterized by increasing demand for mental health services, driven by growing awareness and acceptance of mental health conditions. The competitive landscape includes other mental health providers, psychiatric clinics, and hospitals. Greenbrook differentiates itself through its focus on TMS therapy, a non-invasive treatment option. The industry is subject to regulatory oversight and reimbursement policies, which can impact the financial performance of companies like Greenbrook.
Who Are GBNH's Key Customers?
- Individuals suffering from major depressive disorder.
- Patients with other mental health disorders.
- Individuals seeking non-invasive mental health treatments.
F-Score 4/9Financial Health
Greenbrook TMS Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.72 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -86.3%, showing how much profit it generates from its asset base. A current ratio of 0.51 means current liabilities exceed short-term assets, a liquidity point worth watching.
GBNH Valuation & Market Position
With a $5.52M market cap, Greenbrook TMS Inc. sits in the micro-cap segment of the market. Relative to its peer group, GBNH's quantitative score of 45/100 is roughly in line with the peer average of 48/100.
GBNH Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the growth potential of Greenbrook TMS.
- Community sentiment has been increasingly positive, with discussions highlighting the company's innovative treatment solutions in mental health.
- The overall market perception is shifting towards mental health services, which positions Greenbrook favorably as demand rises.
- Recent partnerships and expansions into new markets have sparked optimism among investors about potential revenue growth.
Bear Case
- Concerns over regulatory changes in the mental health sector have led some investors to question the sustainability of Greenbrook's business model.
- Social sentiment shows a segment of the community worried about competition from emerging mental health technologies that could overshadow Greenbrook's offerings.
- Recent earnings reports have not met some market expectations, leading to skepticism about the company's growth trajectory.
- Overall market volatility has created a cautious atmosphere, causing some traders to adopt a bearish stance on stocks in the healthcare sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
GBNH Latest News
No recent news available for GBNH.
GBNH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GBNH.
Price Targets
Wall Street price target analysis for GBNH.
GBNH MoonshotScore
What does this score mean?
The MoonshotScore rates GBNH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William P. Leonard
CEO
William P. Leonard serves as the CEO of Greenbrook TMS Inc., leading the company's strategic direction and operational execution. His background includes experience in healthcare management and business development. He is responsible for overseeing the company's network of TMS centers and driving growth in the mental health services market. His leadership focuses on expanding access to innovative mental health treatments and improving patient outcomes. He manages a team of 492 employees.
Track Record: Under William P. Leonard's leadership, Greenbrook TMS Inc. has focused on expanding its network of TMS centers and increasing patient access to TMS therapy. Key milestones include the expansion into new geographic markets and the introduction of new psychiatric services. He has overseen the company's efforts to improve operational efficiency and enhance patient care. He has navigated the challenges of the mental healthcare market, focusing on sustainable growth and profitability.
What Investors Ask About Greenbrook TMS Inc. (GBNH) — Healthcare
What does Greenbrook TMS Inc. do?
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. TMS is a non-invasive treatment for major depressive disorder and other mental health disorders. The company's centers provide TMS therapy alongside related psychiatric services, offering patients an alternative to traditional medication and therapy. Greenbrook's business model focuses on providing specialized care through its network of TMS centers, focusing on patient outcomes and expanding access to mental health treatments.
What do analysts say about GBNH stock?
Analyst coverage of Greenbrook TMS Inc. (GBNH) is pending, reflecting the company's small-cap status and recent financial challenges. Key valuation metrics, such as the negative P/E ratio and low gross margin, highlight the need for improved profitability. Growth considerations include the company's ability to expand its network of TMS centers and increase patient throughput. Investors should carefully consider the company's financial performance and competitive landscape before making investment decisions. Further AI analysis is also pending.
What are the main risks for GBNH?
Greenbrook TMS Inc. faces several risks, including competition from alternative mental health treatments, changes in reimbursement policies, and economic downturns affecting patient affordability. The company's negative profit margin and high beta indicate financial instability and volatility. Regulatory compliance challenges and the need for continued investment in infrastructure and technology also pose risks. Investors should carefully assess these risks before investing in GBNH. The company's reliance on insurance reimbursement makes it vulnerable to changes in healthcare policy.
What are the key factors to evaluate for GBNH?
Greenbrook TMS Inc. (GBNH) holds an AI score of 45/100 (low). Not financial advice.
How frequently does GBNH data refresh on this page?
GBNH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GBNH's recent stock price performance?
Greenbrook TMS Inc. (GBNH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized in TMS therapy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GBNH overvalued or undervalued right now?
Valuing Greenbrook TMS Inc. (GBNH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GBNH?
Before investing in Greenbrook TMS Inc. (GBNH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on information available as of 2021.
- AI analysis is pending and may provide additional insights.